Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

• Status: Not yet recruiting
• Trial end date: 2025-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the trial is to establish an individualized first-line treatment incorporating checkpoint inhibition for early-stage unfavorable cHL, which is effective and well tolerated.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cologne

Criteria

Inclusion Criteria:

• Age 18-60 for the main trial cohort

• Age ≥ 61 years and eligible for AVD as determined by CIRS-G score and investigator for the exploratory cohort

• First diagnosis of treatment-naïve cHL

• Early-stage unfavorable disease (i.e. stage IA, IB and IIA with risk factors a-d, stage IIB with risk factors c-d):

1. large mediastinal mass

2. extranodal lesion(s)

3. elevated erythrocyte sedimentation rate

4. ≥ 3 nodal areas

Exclusion Criteria:

• Presence of nodular-lymphocyte predominant Hodgkin lymphoma, grey-zone lymphoma and/or central nervous system involvement of lymphoma